Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease Patients (EASE LID Study)

NCT02136914 is registered in ClinicalTrials.gov with Adamas Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02136914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02136914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease Patients (EASE LID Study)
Lead sponsor
Adamas Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2014
Completion date
December 31, 2015
Enrollment
126 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

dyskinesia, levodopa induced dyskinesia (lid), parkinson's disease